Kimia Farma builds pharmaceutical raw material factory

In cooperation with Sungwun Pharmacopia of South Korea, Indonesias state-owned pharmaceutical company PT Kimia Farma will build the first factory for pharmaceutical raw materials to meet the needs of medicine producers in the country.

The construction of the pharmaceutical factory was inaugurated on Monday by Health Minister Nila F Moeloek, in the company of Kimia Farma President Director Rusdi Rosman, Food and Drug Regulatory Agency (BPOM) Chief Penny Lukito, and House Commission-IX Chairman Dede Yusuf.

Rusdi Rosman said the factory, located at the Lippo industrial area in Cikarang, Bekasi, will be built in stages on a six-hectare plot of land and at a cost of Rp132 billion.

In building the first factory for pharmaceutical raw materials, Kimia Farma will cooperate with Sungwun Pharmacopia Co. Ltd, because of their experience in producing raw materials for medicines.

Further, the Kimia Farma president director noted that the factory will be built in accordance with the standard of Good Manufacturing Practice (GMP) and is expected to be completed by the end of 2017, while the selling of Active Pharmaceutical Raw Materials (API) is planned to begin in early 2018.

Rusdi noted that the factory will produce eight types of raw materials, including Simvastatin, Atorvastatin, Rosuvastatin, Pantoprazole, Esomeprazole, Rabeprazole, Clopidogrel and Sarpogrelate, with a production capacity of 30 tons per year.

Production of the raw materials is to meet 100 percent of the needs of the pharmaceutical industry in Indonesia, as well as for market export.

Kimia Farma will also manufacture seven types of raw materials that can be used for cosmetics and dietary supplements, and to be exported to Korea, Japan and America.